These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 21157293

  • 1. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
    Altuna X, Lopez JP, Yu MA, Arandazi MJ, Harris JP, Wang-Rodriguez J, An Y, Dobrow R, Doherty JK, Ongkeko WM.
    Otol Neurotol; 2011 Jan; 32(1):163-70. PubMed ID: 21157293
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 3. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 01; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Aug 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 5. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A.
    Cancer Res; 2009 Jun 15; 69(12):5099-107. PubMed ID: 19509233
    [Abstract] [Full Text] [Related]

  • 6. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 7. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P, Gao WY, Turner S, Ducatman BS.
    Mol Cancer; 2003 Jan 03; 2():1. PubMed ID: 12537587
    [Abstract] [Full Text] [Related]

  • 8. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.
    J Cutan Pathol; 2006 Apr 03; 33(4):280-5. PubMed ID: 16630177
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E.
    Exp Oncol; 2007 Jun 03; 29(2):126-31. PubMed ID: 17704745
    [Abstract] [Full Text] [Related]

  • 11. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, Riva P.
    Oncol Rep; 2007 Jul 03; 18(1):249-52. PubMed ID: 17549375
    [Abstract] [Full Text] [Related]

  • 12. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 03; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines.
    Mayorga ME, Sanchis D, Perez de Santos AM, Velasco A, Dolcet X, Casanova JM, Baradad M, Egido R, Pallares J, Espurz N, Benitez D, Mila J, Malvehy J, Castel T, Comella JX, Matias-Guiu X, Vilella R, Marti RM.
    Melanoma Res; 2006 Apr 03; 16(2):127-35. PubMed ID: 16567968
    [Abstract] [Full Text] [Related]

  • 15. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
    Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA.
    Anticancer Res; 2010 Feb 03; 30(2):547-52. PubMed ID: 20332468
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.
    Reprod Sci; 2008 Sep 03; 15(7):673-7. PubMed ID: 18492696
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L.
    Cancer; 2002 Dec 01; 95(11):2373-9. PubMed ID: 12436445
    [Abstract] [Full Text] [Related]

  • 20. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.